CymaBay Therapeutics, Inc.
Treatment of intestinal barrier dysfunction and associated diseases
Last updated:
Abstract:
Treatment of intestinal barrier dysfunction and associated diseases other than alcoholic liver disease or NAFLD/NASH with seladelpar or a salt thereof.
Status:
Application
Type:
Utility
Filling date:
12 Nov 2020
Issue date:
20 May 2021